Sponsored
Article Tools

Intercell reports Phase II Study Results of its Vaccine Enhancement Patch for Pandemic Influenza

Published: July 2, 2010; 00:00 · (Vindobona)

Intercell AG today announced the results of a Phase II clinical trial of its investigational Vaccine Enhancement Patch (VEP) system for avian H5N1 influenza.

Intercell reports Phase II Study Results of its Vaccine Enhancement Patch for Pandemic Influenza / Picture: © Intercell

Intercell AG (VSE: ICLL) today announced the results of a Phase II clinical trial of its investigational Vaccine Enhancement Patch (VEP) system for avian H5N1 influenza.

In this development program, Intercell is working under a contract with the U.S. Department of Health and Human Services (HHS) to develop a dose-sparing approach with potential for a single dose immunization…

This article includes a total of 365 words.

or Log In